MeSH term
Frequency | Condition_Probility | Female | 310 | 0.0 |
Humans | 958 | 0.0 |
Pregnancy | 17 | 0.0 |
Randomized Controlled Trials | 3 | 0.0 |
Aged | 134 | 0.0 |
Aged, 80 and over | 33 | 0.0 |
Computer Simulation | 6 | 1.0 |
Crystallography, X-Ray | 2 | 0.0 |
Cytochrome P-450 Enzyme System/chemistry | 2 | 33.0 |
DNA Primers/chemistry | 8 | 0.0 |
DNA, Complementary/metabolism | 10 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Models, Molecular | 8 | 0.0 |
Mutagenesis | 4 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Mutation | 21 | 0.0 |
Protein Conformation | 5 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 501 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
*Aryl Hydrocarbon Hydroxylases | 99 | 11.0 |
Cytochrome P-450 CYP2E1/*genetics | 117 | 95.0 |
Cytochrome P-450 Enzyme System/*genetics | 53 | 12.0 |
Gene Deletion | 3 | 0.0 |
Male | 419 | 0.0 |
Mixed Function Oxygenases/*genetics | 9 | 6.0 |
Polymorphism, Genetic | 64 | 1.0 |
Adult | 276 | 0.0 |
Cells, Cultured | 61 | 0.0 |
Comet Assay | 4 | 5.0 |
Cytochrome P-450 CYP2E1/genetics | 30 | 78.0 |
Genotype | 138 | 1.0 |
Italy | 3 | 0.0 |
Lymphocytes/*drug effects | 2 | 4.0 |
Middle Aged | 238 | 0.0 |
Mutagens/*adverse effects | 2 | 33.0 |
Questionnaires | 7 | 1.0 |
Sister Chromatid Exchange | 2 | 4.0 |
Smoking | 16 | 4.0 |
Antibodies/pharmacology | 3 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 29 | 22.0 |
Enzyme Inhibitors/pharmacology | 50 | 1.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 18 | 25.0 |
Kinetics | 108 | 1.0 |
Microsomes, Liver/drug effects/*enzymology | 10 | 23.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 6 | 13.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/*metabolism | 2 | 11.0 |
Transfection | 47 | 0.0 |
Animals | 283 | 0.0 |
Antioxidants/*pharmacology | 3 | 2.0 |
Apoptosis | 5 | 0.0 |
Carcinoma, Hepatocellular/*enzymology/pathology | 2 | 16.0 |
Cytochrome P-450 CYP2E1/*metabolism | 57 | 98.0 |
Drug Synergism | 9 | 0.0 |
Glutathione/metabolism | 13 | 6.0 |
Liver Neoplasms/*enzymology/pathology | 2 | 20.0 |
Oxidative Stress/drug effects | 3 | 6.0 |
Reactive Oxygen Species/metabolism/*pharmacology | 2 | 66.0 |
Research Support, U.S. Gov't, P.H.S. | 252 | 0.0 |
Up-Regulation | 5 | 0.0 |
Alanine Transaminase/blood | 6 | 3.0 |
Diet | 6 | 1.0 |
Glucose/administration & dosage | 2 | 6.0 |
Liver/*enzymology/pathology | 3 | 27.0 |
Mice | 64 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Microsomes, Liver/enzymology | 47 | 21.0 |
Polymerase Chain Reaction | 72 | 0.0 |
RNA, Messenger/analysis | 18 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 36 | 0.0 |
Biotransformation | 69 | 12.0 |
Cytochrome P-450 Enzyme System/*metabolism | 104 | 20.0 |
Imines/*metabolism | 2 | 66.0 |
Isoenzymes/metabolism | 39 | 7.0 |
Oxidation-Reduction | 59 | 4.0 |
Recombinant Proteins/metabolism | 36 | 1.0 |
Solvents | 3 | 5.0 |
Spectrophotometry, Ultraviolet | 9 | 5.0 |
Substrate Specificity | 65 | 2.0 |
Alcohol Dehydrogenase/*genetics | 13 | 14.0 |
Alcohol Drinking/*genetics/*metabolism | 2 | 66.0 |
Aldehyde Dehydrogenase/*genetics | 18 | 10.0 |
Asian Continental Ancestry Group/*genetics | 7 | 2.0 |
Body Mass Index | 5 | 0.0 |
Central Nervous System Depressants/*metabolism | 2 | 50.0 |
Ethanol/*metabolism | 11 | 40.0 |
Japan | 32 | 2.0 |
Polymorphism, Genetic/*genetics | 26 | 2.0 |
Carcinogens/pharmacokinetics | 6 | 40.0 |
Cytochrome P-450 CYP2E1/metabolism | 36 | 83.0 |
Microsomes, Liver/*enzymology | 50 | 25.0 |
Mixed Function Oxygenases/metabolism | 25 | 17.0 |
Recombinant Proteins | 6 | 0.0 |
Trihalomethanes/*pharmacokinetics | 2 | 100.0 |
Comparative Study | 132 | 0.0 |
Cytochrome P-450 CYP1A2/metabolism | 24 | 24.0 |
Cytochrome P-450 CYP2B1/metabolism | 4 | 36.0 |
Rats | 154 | 1.0 |
Chlorzoxazone/pharmacology | 3 | 50.0 |
Coumarins/pharmacology | 4 | 21.0 |
Enzymes/*metabolism | 4 | 26.0 |
Ketoconazole/pharmacology | 10 | 10.0 |
Microsomes, Liver/drug effects/*metabolism | 13 | 32.0 |
Models, Biological | 14 | 0.0 |
Quinidine/pharmacology | 5 | 11.0 |
Sulfaphenazole/pharmacology | 7 | 24.0 |
Theophylline/*analogs & derivatives/pharmacology | 2 | 18.0 |
Antibodies/immunology | 3 | 0.0 |
Blotting, Western | 48 | 0.0 |
Immunohistochemistry | 24 | 0.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
DNA Mutational Analysis | 8 | 0.0 |
Disease-Free Survival | 4 | 0.0 |
English Abstract | 44 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Glutathione Transferase/*genetics | 40 | 5.0 |
Neoplasm Staging | 2 | 0.0 |
Prognosis | 7 | 0.0 |
Survival Rate | 2 | 0.0 |
Case-Control Studies | 61 | 1.0 |
Child | 17 | 0.0 |
Child, Preschool | 11 | 0.0 |
Cytochrome P-450 CYP2E1/*biosynthesis/genetics | 11 | 100.0 |
*Environmental Exposure | 2 | 2.0 |
*Gene Expression Regulation | 2 | 0.0 |
Infant | 11 | 0.0 |
Infant, Newborn | 12 | 0.0 |
Odds Ratio | 16 | 1.0 |
*Polymorphism, Genetic | 102 | 2.0 |
Risk Assessment | 15 | 1.0 |
Administration, Oral | 12 | 1.0 |
Dose-Response Relationship, Drug | 44 | 0.0 |
Drug Interactions | 48 | 4.0 |
Enzyme Inhibitors | 4 | 4.0 |
Great Britain | 2 | 0.0 |
Inhalation Exposure | 4 | 19.0 |
Monte Carlo Method | 2 | 2.0 |
*Occupational Exposure | 10 | 7.0 |
Area Under Curve | 15 | 3.0 |
Gene Expression Regulation, Enzymologic/*physiology | 6 | 6.0 |
*Sex Characteristics | 4 | 2.0 |
Statistics, Nonparametric | 4 | 0.0 |
Variation (Genetics)/*physiology | 2 | 16.0 |
African Continental Ancestry Group/genetics | 6 | 2.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 3 | 2.0 |
Asian Continental Ancestry Group/genetics | 12 | 3.0 |
Egypt | 2 | 4.0 |
European Continental Ancestry Group/genetics | 17 | 2.0 |
*Gene Frequency | 3 | 0.0 |
Pharmacogenetics | 5 | 4.0 |
Apoptosis/drug effects/*physiology | 3 | 1.0 |
DNA Fragmentation/drug effects | 4 | 4.0 |
Enzyme Inhibitors/*pharmacology | 36 | 5.0 |
Reactive Oxygen Species/*metabolism | 6 | 3.0 |
Tumor Cells, Cultured | 59 | 0.0 |
Pharmaceutical Preparations/*metabolism | 20 | 21.0 |
*Pharmacokinetics | 6 | 13.0 |
Catalysis | 28 | 3.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 23 | 19.0 |
In Vitro | 80 | 1.0 |
Isoenzymes/antagonists & inhibitors | 7 | 17.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 4 | 13.0 |
Hydroxylation | 47 | 13.0 |
Isoenzymes/chemistry/metabolism | 4 | 14.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 43 | 0.0 |
Cytochrome P-450 CYP2E1/*biosynthesis | 17 | 94.0 |
Enzyme Induction | 38 | 6.0 |
Liver/*enzymology | 26 | 5.0 |
Rats, Sprague-Dawley | 48 | 2.0 |
Anti-Infective Agents/*pharmacology | 3 | 9.0 |
Chromatography, High Pressure Liquid | 67 | 3.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 15 | 21.0 |
Microsomes, Liver/drug effects/enzymology | 23 | 23.0 |
Recombinant Proteins/antagonists & inhibitors | 5 | 10.0 |
*Steroid 16-alpha-Hydroxylase | 20 | 10.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 3 | 33.0 |
Blotting, Northern | 7 | 0.0 |
Cell Survival/drug effects | 16 | 1.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 3 | 7.0 |
Gene Expression | 31 | 0.0 |
Hepatocytes/*drug effects/enzymology | 2 | 14.0 |
Protein Isoforms | 6 | 0.0 |
RNA, Messenger/metabolism | 24 | 0.0 |
Age Factors | 11 | 0.0 |
Alcohol Drinking | 5 | 3.0 |
Aldehyde Dehydrogenase/genetics | 6 | 20.0 |
Antibodies/*immunology | 3 | 2.0 |
Carcinogens/*adverse effects | 3 | 13.0 |
Cohort Studies | 8 | 0.0 |
DNA-Binding Proteins/*genetics | 4 | 0.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Glutathione Transferase/genetics | 23 | 7.0 |
Occupational Exposure/*adverse effects | 6 | 6.0 |
Prevalence | 3 | 0.0 |
Taiwan/epidemiology | 6 | 5.0 |
Vinyl Chloride/*adverse effects | 2 | 40.0 |
Cytochrome P-450 CYP2E1/physiology | 4 | 100.0 |
Cytochrome P-450 Enzyme System/*physiology | 12 | 20.0 |
Databases, Factual | 3 | 1.0 |
Quantitative Structure-Activity Relationship | 3 | 10.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 3 | 16.0 |
Models, Theoretical | 2 | 1.0 |
Aspartate Aminotransferases/blood | 6 | 4.0 |
Drug Therapy, Combination | 2 | 0.0 |
Ethanol/pharmacology | 12 | 19.0 |
Liver/*drug effects | 2 | 13.0 |
Nutrition | 2 | 5.0 |
Cell Line | 50 | 0.0 |
Cytochrome P-450 CYP2E1/genetics/*metabolism | 16 | 100.0 |
Enzyme Activation | 13 | 0.0 |
Hamsters | 8 | 0.0 |
Aflatoxin B1/metabolism | 2 | 25.0 |
Mice, Knockout | 10 | 0.0 |
Mutagenicity Tests | 13 | 8.0 |
Enzyme Inhibitors/administration & dosage/*pharmacology | 2 | 12.0 |
Inhibitory Concentration 50 | 6 | 2.0 |
Alkylating Agents/metabolism | 2 | 66.0 |
Carcinoma, Squamous Cell/enzymology | 2 | 20.0 |
Cytochrome P-450 Enzyme System/*biosynthesis | 9 | 10.0 |
Esophagus/*enzymology | 3 | 75.0 |
Microsomes/enzymology | 21 | 20.0 |
Mixed Function Oxygenases/*biosynthesis | 4 | 20.0 |
Mouth Mucosa/*enzymology | 2 | 50.0 |
Time Factors | 27 | 0.0 |
Microsomes, Liver/drug effects/metabolism | 8 | 17.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 5 | 16.0 |
Coumarins/*metabolism | 4 | 26.0 |
Microsomes, Liver/enzymology/metabolism | 11 | 16.0 |
Rats, Inbred F344 | 9 | 2.0 |
Adolescent | 44 | 0.0 |
Cytochrome P-450 Enzyme System/*analysis | 3 | 15.0 |
Isoenzymes/*metabolism | 19 | 6.0 |
Oxidoreductases, N-Demethylating/analysis | 2 | 50.0 |
Species Specificity | 27 | 0.0 |
Cell Culture Techniques | 4 | 0.0 |
Flavonoids/*pharmacology | 3 | 3.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cytochromes b5/*metabolism | 3 | 50.0 |
Escherichia coli | 3 | 0.0 |
Microsomes, Liver/metabolism | 24 | 13.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Buthionine Sulfoximine/pharmacology | 8 | 22.0 |
Cytosol/*enzymology | 2 | 3.0 |
Flow Cytometry | 5 | 0.0 |
Genetic Vectors | 5 | 0.0 |
Glutathione/*physiology | 2 | 22.0 |
Lipid Peroxidation/drug effects | 10 | 18.0 |
Membrane Potentials/drug effects | 6 | 4.0 |
Reactive Oxygen Species/metabolism | 13 | 4.0 |
Tetrazolium Salts | 2 | 3.0 |
Thiazoles | 2 | 3.0 |
Acetyltransferases/*genetics | 3 | 5.0 |
DNA Repair/*genetics | 3 | 0.0 |
Disease Susceptibility | 16 | 2.0 |
NAD(P)H Dehydrogenase (Quinone)/*genetics | 3 | 4.0 |
Treatment Outcome | 2 | 0.0 |
Xenobiotics/metabolism | 4 | 9.0 |
Biological Markers/urine | 3 | 4.0 |
Cytochrome P-450 CYP1A1/genetics | 18 | 18.0 |
Deoxyguanosine/*analogs & derivatives/urine | 2 | 33.0 |
*Genetic Predisposition to Disease | 23 | 2.0 |
Peroxidase/genetics | 2 | 15.0 |
Polymorphism, Restriction Fragment Length | 38 | 1.0 |
Alcohol Dehydrogenase/genetics | 4 | 17.0 |
Genetic Predisposition to Disease | 36 | 1.0 |
Metabolism/*genetics | 3 | 50.0 |
NAD(P)H Dehydrogenase (Quinone)/genetics | 4 | 23.0 |
Alleles | 57 | 0.0 |
Benzene/*adverse effects | 2 | 33.0 |
Environmental Exposure/*adverse effects | 2 | 7.0 |
Gene Frequency | 37 | 0.0 |
Genetics, Population | 9 | 2.0 |
Point Mutation | 5 | 0.0 |
Acrylonitrile/*metabolism/toxicity | 2 | 100.0 |
Cytochrome P-450 CYP2E1/*genetics/metabolism | 20 | 95.0 |
Antitubercular Agents/*pharmacology | 4 | 36.0 |
Biological Markers | 5 | 0.0 |
Isoniazid/*pharmacology | 5 | 38.0 |
NADP/metabolism | 11 | 9.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors | 3 | 6.0 |
Disulfiram/pharmacology | 3 | 33.0 |
Ditiocarb/pharmacology | 9 | 52.0 |
Pyrazoles/pharmacology | 11 | 22.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
Cytochrome P-450 CYP2E1 | 58 | 57.0 |
*DNA Adducts | 2 | 5.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Esophageal Neoplasms/*genetics | 4 | 5.0 |
Phosphorus Radioisotopes | 2 | 3.0 |
China | 4 | 0.0 |
Stomach Neoplasms/*ethnology/*genetics | 2 | 66.0 |
Chlorzoxazone/metabolism/pharmacology | 2 | 100.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 2 | 15.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/metabolism | 2 | 33.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/metabolism | 4 | 80.0 |
Disulfiram/*pharmacology | 4 | 57.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 6 | 31.0 |
Body Weight/drug effects | 2 | 1.0 |
Cytochrome P-450 CYP2E1/drug effects/metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/drug effects/*metabolism | 3 | 13.0 |
Cytochrome P-450 CYP2E1/immunology/*metabolism | 2 | 100.0 |
Liver Diseases, Alcoholic/*immunology | 2 | 33.0 |
Protein Binding | 19 | 0.0 |
Age Distribution | 4 | 1.0 |
Base Sequence | 60 | 0.0 |
China/epidemiology | 4 | 2.0 |
Incidence | 5 | 0.0 |
Logistic Models | 8 | 1.0 |
Molecular Sequence Data | 57 | 0.0 |
Risk Factors | 75 | 1.0 |
Sampling Studies | 2 | 1.0 |
Sex Distribution | 2 | 0.0 |
Liver/*drug effects/enzymology | 6 | 13.0 |
Mitochondria, Liver/drug effects/metabolism | 2 | 50.0 |
Oxidative Stress | 15 | 4.0 |
Xenobiotics/toxicity | 2 | 25.0 |
COS Cells | 4 | 0.0 |
Cysteine Endopeptidases/*metabolism | 5 | 2.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/genetics/*metabolism | 3 | 100.0 |
Gene Expression Regulation, Enzymologic/physiology | 6 | 7.0 |
Heat | 3 | 0.0 |
Hela Cells | 5 | 0.0 |
Multienzyme Complexes/*metabolism | 5 | 3.0 |
Proteasome Endopeptidase Complex | 7 | 1.0 |
Rabbits | 25 | 0.0 |
Tetracycline/*pharmacology | 2 | 11.0 |
Microsomes, Liver/*metabolism | 27 | 15.0 |
Models, Chemical | 10 | 2.0 |
Oxidoreductases, N-Demethylating/*metabolism | 13 | 15.0 |
Alcohol Drinking/*metabolism | 3 | 33.0 |
Alcoholism/metabolism | 2 | 33.0 |
Carcinogens | 3 | 3.0 |
Ethanol/pharmacokinetics | 6 | 30.0 |
France/epidemiology | 2 | 1.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
DNA/genetics | 5 | 0.0 |
Parkinson Disease/enzymology/*genetics | 2 | 20.0 |
Antioxidants/pharmacology | 14 | 7.0 |
Arachidonic Acid/pharmacology | 3 | 7.0 |
Coculture Techniques | 3 | 0.0 |
Drug Combinations | 3 | 0.0 |
Ferric Compounds/pharmacology | 3 | 27.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Hydrogen Peroxide/metabolism | 7 | 5.0 |
Lipid Peroxidation | 8 | 7.0 |
Nitrilotriacetic Acid/*analogs & derivatives/pharmacology | 3 | 100.0 |
Vitamin E/pharmacology | 4 | 12.0 |
Hepatocytes/*metabolism | 2 | 4.0 |
*Oxidative Stress | 7 | 3.0 |
*Reactive Oxygen Species | 2 | 7.0 |
Lung Neoplasms/*genetics | 11 | 4.0 |
Multivariate Analysis | 4 | 0.0 |
Smoking/adverse effects | 16 | 5.0 |
Mutagenicity Tests/*methods | 4 | 15.0 |
Nitrosamines/*toxicity | 2 | 20.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 2 | 12.0 |
Tobacco | 3 | 10.0 |
Breast/*enzymology | 2 | 13.0 |
Gene Expression Regulation, Enzymologic | 16 | 2.0 |
Gene Expression Regulation, Neoplastic | 6 | 0.0 |
RNA, Messenger/genetics | 15 | 0.0 |
Biological Markers/*urine | 2 | 16.0 |
Italy/epidemiology | 2 | 0.0 |
Workplace | 2 | 40.0 |
Alcohol Dehydrogenase/*genetics/physiology | 2 | 66.0 |
Aldehyde Dehydrogenase/*genetics/physiology | 2 | 50.0 |
Chromosome Mapping | 4 | 0.0 |
Isoenzymes/*genetics/physiology | 3 | 30.0 |
Carcinogens/adverse effects | 3 | 21.0 |
Cytochrome P-450 CYP2E1/biosynthesis/*metabolism | 6 | 100.0 |
Nitrosamines/adverse effects | 2 | 100.0 |
Carcinogens/*pharmacology | 2 | 3.0 |
Cell Line, Transformed | 7 | 0.0 |
Electrophoretic Mobility Shift Assay | 3 | 0.0 |
Enzyme Induction/drug effects | 17 | 4.0 |
NF-kappa B/metabolism | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 13 | 12.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
Korea | 4 | 1.0 |
Liver Cirrhosis, Alcoholic/enzymology/*genetics | 2 | 40.0 |
*Polymorphism, Restriction Fragment Length | 20 | 2.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 11 | 15.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
RNA, Messenger/*biosynthesis | 4 | 1.0 |
Rifampin/*pharmacology | 3 | 6.0 |
Antioxidants/metabolism | 3 | 3.0 |
Carcinoma, Hepatocellular | 13 | 3.0 |
Ethanol/*toxicity | 7 | 21.0 |
Liver Neoplasms | 11 | 3.0 |
Oxidative Stress/*drug effects | 4 | 10.0 |
Alkane 1-Monooxygenase | 10 | 32.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 5 | 16.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 30 | 20.0 |
Electrophoresis, Polyacrylamide Gel | 9 | 0.0 |
Microsomes/metabolism | 9 | 7.0 |
Mixed Function Oxygenases/genetics/*metabolism | 3 | 6.0 |
Caffeine/pharmacokinetics | 2 | 15.0 |
Chlorzoxazone/*pharmacokinetics | 5 | 83.0 |
Cross-Over Studies | 8 | 1.0 |
Debrisoquin/pharmacokinetics | 2 | 50.0 |
Muscle Relaxants, Central/*pharmacokinetics | 3 | 75.0 |
Hydroxylation/drug effects | 4 | 11.0 |
Microsomes, Liver/*drug effects/enzymology | 8 | 23.0 |
Steroid Hydroxylases/antagonists & inhibitors/metabolism | 4 | 44.0 |
Tolbutamide/metabolism | 3 | 20.0 |
Mass Screening/*methods | 2 | 3.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 10 | 6.0 |
Plant Extracts/*toxicity | 2 | 40.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 3 | 42.0 |
Nitrosamines/metabolism/*toxicity | 2 | 66.0 |
Plasmids/genetics | 3 | 0.0 |
Recombinant Proteins/genetics/metabolism | 8 | 1.0 |
Chlorzoxazone/metabolism | 18 | 90.0 |
Cytochrome P-450 CYP2D6/metabolism | 12 | 30.0 |
Mephenytoin/metabolism | 2 | 12.0 |
Metoprolol/metabolism | 2 | 100.0 |
Oxidoreductases, N-Demethylating/metabolism | 7 | 13.0 |
Arylamine N-Acetyltransferase/genetics | 6 | 10.0 |
DNA Damage | 5 | 0.0 |
Isoenzymes/genetics | 8 | 2.0 |
*Mutation | 7 | 0.0 |
Pancreatic Neoplasms/*genetics | 2 | 2.0 |
Antibiotics, Antitubercular/pharmacology | 2 | 22.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Reproducibility of Results | 8 | 0.0 |
Cytochrome P-450 CYP2E1/*antagonists & inhibitors | 6 | 100.0 |
Rats, Wistar | 30 | 2.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
Environmental Monitoring | 4 | 10.0 |
Phenotype | 38 | 0.0 |
Micronucleus Tests | 7 | 14.0 |
Biological Markers/analysis | 3 | 0.0 |
Volatilization | 2 | 28.0 |
Chi-Square Distribution | 3 | 0.0 |
Cytochrome P-450 CYP1A1/*genetics | 16 | 8.0 |
Lung Neoplasms/epidemiology/*genetics | 2 | 14.0 |
Binding Sites | 9 | 0.0 |
DNA/analysis | 9 | 1.0 |
Gene Expression/drug effects | 4 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Interleukin-4/*pharmacology | 3 | 1.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Transcription Factors | 3 | 3.0 |
Cytochrome P-450 CYP2E1/genetics/metabolism | 11 | 91.0 |
Enzymes/*genetics/metabolism | 2 | 22.0 |
Glutathione Transferase/genetics/metabolism | 9 | 7.0 |
Industry | 2 | 6.0 |
Naphthols/*urine | 4 | 80.0 |
Occupational Exposure | 6 | 7.0 |
Polycyclic Hydrocarbons, Aromatic/metabolism | 2 | 40.0 |
Pyrenes/*analysis | 2 | 33.0 |
Mixed Function Oxygenases/*metabolism | 18 | 12.0 |
Saccharomyces cerevisiae/enzymology | 2 | 3.0 |
Genetic Engineering | 4 | 4.0 |
Mixed Function Oxygenases/genetics/metabolism | 7 | 31.0 |
Salmonella typhimurium/drug effects/genetics | 2 | 14.0 |
Biopsy, Needle | 2 | 0.0 |
Liver/enzymology | 21 | 3.0 |
Transcription, Genetic | 18 | 0.0 |
Bronchi/cytology/*enzymology | 3 | 42.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Ethanol/administration & dosage/*pharmacology | 2 | 40.0 |
Arachidonic Acid/*pharmacology | 2 | 12.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Cytochrome P-450 CYP2E1/drug effects/*metabolism | 6 | 100.0 |
Hepatocytes/drug effects | 2 | 16.0 |
Lipid Peroxidation/*drug effects | 3 | 9.0 |
Mitochondria/drug effects/metabolism | 3 | 9.0 |
Models, Animal | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Indoles/*metabolism/pharmacology | 2 | 50.0 |
Liver/*metabolism | 11 | 2.0 |
Phenacetin/metabolism | 4 | 36.0 |
Theophylline/metabolism | 3 | 23.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics/metabolism | 2 | 13.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/genetics/metabolism | 2 | 100.0 |
Genetic Predisposition to Disease/genetics | 8 | 1.0 |
Cell Survival | 3 | 0.0 |
Dogs | 8 | 0.0 |
Glucuronides/metabolism | 2 | 4.0 |
Hepatocytes/*enzymology | 4 | 26.0 |
Nitrophenols/metabolism | 8 | 36.0 |
Sulfates/metabolism | 2 | 3.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/*metabolism | 5 | 100.0 |
Epoxide Hydrolases/metabolism | 5 | 31.0 |
Epoxy Compounds/metabolism | 4 | 50.0 |
Chromosome Aberrations | 3 | 0.0 |
Epoxide Hydrolases/genetics | 4 | 30.0 |
Metabolic Detoxication, Drug | 10 | 12.0 |
Styrene/*adverse effects/metabolism | 2 | 100.0 |
Liver/metabolism | 14 | 1.0 |
Oxygen/*metabolism | 2 | 1.0 |
Temperature | 2 | 0.0 |
Ethanol/administration & dosage/*adverse effects | 2 | 66.0 |
Hepatocytes/drug effects/*enzymology | 2 | 18.0 |
Macaca fascicularis | 8 | 2.0 |
Cytokines/genetics/metabolism | 2 | 6.0 |
Epidemiology, Molecular | 3 | 3.0 |
Regression Analysis | 17 | 1.0 |
Alcoholism/*genetics | 9 | 9.0 |
DNA/blood | 4 | 2.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Baculoviridae | 3 | 5.0 |
Gene Expression Regulation | 2 | 0.0 |
Insects | 3 | 1.0 |
Isoenzymes | 6 | 3.0 |
Liver/drug effects/*enzymology | 4 | 10.0 |
Microsomes, Liver | 2 | 20.0 |
Cytochrome P-450 Enzyme System/physiology | 4 | 15.0 |
Mixed Function Oxygenases/physiology | 2 | 16.0 |
Hepatocytes/metabolism | 2 | 2.0 |
Piperazines/*metabolism | 2 | 40.0 |
Carcinoma, Hepatocellular/genetics | 2 | 7.0 |
Liver Neoplasms/genetics | 2 | 9.0 |
Cytochrome P-450 CYP1A1 | 7 | 16.0 |
Steroid Hydroxylases/metabolism | 14 | 22.0 |
Analysis of Variance | 12 | 0.0 |
Cytochrome P-450 Enzyme System/metabolism | 24 | 9.0 |
Glutathione/pharmacology | 2 | 5.0 |
Microsomes, Liver/drug effects/enzymology/*metabolism | 5 | 27.0 |
Catalase/metabolism | 3 | 4.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Tissue Distribution | 11 | 0.0 |
Adrenal Cortex/metabolism | 2 | 11.0 |
Antifungal Agents/*pharmacology | 2 | 4.0 |
Cattle | 4 | 0.0 |
Kidney/metabolism | 3 | 0.0 |
Mitochondria/metabolism | 3 | 1.0 |
Pharmaceutical Preparations/metabolism | 6 | 18.0 |
Triazoles/*pharmacology | 2 | 15.0 |
Asia/epidemiology | 2 | 12.0 |
Enzymes/genetics | 2 | 6.0 |
Chlorzoxazone/*pharmacology | 3 | 100.0 |
Pilot Projects | 2 | 0.0 |
DNA/drug effects/metabolism | 3 | 7.0 |
Enzyme Activation/drug effects | 6 | 0.0 |
Imidazoles/pharmacology | 3 | 1.0 |
NF-kappa B/*metabolism | 3 | 0.0 |
Pyridines/pharmacology | 3 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Mice, Inbred Strains | 5 | 0.0 |
Ethanol/*adverse effects | 5 | 20.0 |
Exons | 8 | 0.0 |
Heterozygote | 10 | 0.0 |
Homozygote | 14 | 0.0 |
Liver Diseases/*genetics | 2 | 22.0 |
Beverages | 3 | 11.0 |
Cytochrome P-450 CYP1A1/metabolism | 11 | 16.0 |
NADPH-Ferrihemoprotein Reductase/metabolism | 5 | 21.0 |
Cytochrome P-450 Enzyme System/*chemistry/*metabolism | 3 | 17.0 |
Hepatocytes/*drug effects/*metabolism | 2 | 40.0 |
Acetaminophen/pharmacology | 2 | 28.0 |
Binding, Competitive | 9 | 0.0 |
Caffeine/metabolism | 2 | 7.0 |
Mass Fragmentography | 12 | 5.0 |
Binding, Competitive/drug effects | 3 | 4.0 |
Thiocyanates/*pharmacology | 2 | 16.0 |
DNA Adducts | 2 | 2.0 |
Models, Statistical | 2 | 1.0 |
Alkylation | 4 | 5.0 |
Cross-Sectional Studies | 3 | 0.0 |
Cytochrome P-450 CYP2D6/*genetics | 11 | 18.0 |
*DNA Repair | 3 | 0.0 |
Glutathione Transferase/*genetics/metabolism | 4 | 5.0 |
Acetyltransferases/genetics | 2 | 5.0 |
Cytochrome P-450 CYP2D6/genetics | 5 | 16.0 |
Alcohol Drinking/*genetics | 2 | 11.0 |
Ethanol/administration & dosage | 2 | 18.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
gamma-Glutamyltransferase/blood | 3 | 6.0 |
Actins/genetics | 3 | 2.0 |
Leukocytes, Mononuclear/*enzymology | 2 | 8.0 |
Liver Diseases, Alcoholic/*enzymology | 3 | 37.0 |
Reference Values | 23 | 0.0 |
Alcoholism/*enzymology/genetics | 3 | 50.0 |
Cytochrome P-450 CYP2E1/*genetics/*metabolism | 4 | 100.0 |
Epoxide Hydrolases/*genetics | 5 | 15.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 2 | 5.0 |
Variation (Genetics) | 4 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Sensitivity and Specificity | 10 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 9 | 18.0 |
Life Style | 4 | 3.0 |
*Smoking | 5 | 6.0 |
Alcoholism/genetics | 3 | 12.0 |
Cytochrome P-450 CYP2E1/classification/genetics | 2 | 100.0 |
Gene Frequency/genetics | 10 | 2.0 |
Los Angeles | 3 | 18.0 |
Mexican Americans/*genetics | 4 | 16.0 |
Benzene/toxicity | 2 | 40.0 |
Administration, Inhalation | 3 | 1.0 |
Adenoviridae/genetics | 2 | 0.0 |
Cytochrome P-450 CYP2E1/*drug effects/metabolism | 3 | 100.0 |
Disease Models, Animal | 6 | 0.0 |
Drug Tolerance | 2 | 1.0 |
Oleic Acid/*metabolism | 2 | 66.0 |
Central Nervous System Depressants/*pharmacology | 2 | 12.0 |
Ethanol/*pharmacology | 11 | 10.0 |
Hepatocytes/*drug effects/metabolism | 2 | 18.0 |
*Proteasome Endopeptidase Complex | 2 | 3.0 |
Central Nervous System Depressants/pharmacology | 2 | 16.0 |
China/ethnology | 2 | 1.0 |
Heterozygote Detection | 4 | 0.0 |
Alcohol Drinking/adverse effects | 7 | 14.0 |
Haplotypes/genetics | 2 | 0.0 |
Mouth Neoplasms/*genetics | 2 | 4.0 |
Epithelial Cells/enzymology | 4 | 11.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 3 | 21.0 |
*Transfection | 2 | 0.0 |
Carcinogens/metabolism/*toxicity | 3 | 30.0 |
Drug Evaluation, Preclinical | 3 | 1.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 5 | 11.0 |
DNA, Complementary | 18 | 0.0 |
Cell Fractionation | 2 | 0.0 |
Isoenzymes/*biosynthesis | 3 | 4.0 |
Microsomes, Liver/*drug effects/metabolism | 4 | 30.0 |
Gene Frequency/*genetics | 2 | 1.0 |
Necrosis | 5 | 1.0 |
DNA Primers | 23 | 0.0 |
*Life Style | 3 | 5.0 |
Taiwan | 6 | 3.0 |
Glutathione Transferase/*metabolism | 3 | 9.0 |
Xenobiotics/*metabolism | 15 | 27.0 |
B-Lymphocytes/enzymology | 4 | 11.0 |
Cytochrome P-450 CYP1A2/*metabolism | 4 | 5.0 |
*Flavonoids | 2 | 8.0 |
Liver Neoplasms, Experimental | 4 | 8.0 |
Steroid Hydroxylases/*metabolism | 6 | 18.0 |
Administration, Cutaneous | 2 | 2.0 |
Chronic Disease | 6 | 0.0 |
Arachidonic Acid/*toxicity | 3 | 100.0 |
Nitrogen Oxides/pharmacology | 2 | 66.0 |
Cytochrome P-450 CYP1A2/*genetics | 4 | 10.0 |
Liver/*drug effects/pathology | 2 | 22.0 |
Ethanol/adverse effects | 2 | 12.0 |
Nutritional Status | 3 | 2.0 |
Vitamin A/metabolism | 2 | 10.0 |
beta Carotene/metabolism | 2 | 100.0 |
Molecular Weight | 2 | 0.0 |
Triglycerides/blood | 3 | 0.0 |
Allyl Compounds/pharmacology | 4 | 100.0 |
Apoptosis/drug effects | 5 | 0.0 |
Chromans/pharmacology | 4 | 17.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 8 | 18.0 |
Hepatocytes/cytology/*drug effects/*metabolism | 2 | 100.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Sulfides/pharmacology | 3 | 60.0 |
Amino Acid Sequence | 18 | 0.0 |
Antibodies | 3 | 0.0 |
Tetrachlorodibenzodioxin | 2 | 28.0 |
Peroxides/metabolism | 3 | 23.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Anticarcinogenic Agents/*metabolism | 2 | 40.0 |
Cytochrome P-450 CYP2E1/*antagonists & inhibitors/metabolism | 8 | 100.0 |
Nitrosamines/*metabolism | 2 | 20.0 |
*Plants, Medicinal | 2 | 2.0 |
Rodentia | 3 | 3.0 |
Cytochrome P-450 CYP1A2/*antagonists & inhibitors/metabolism | 3 | 27.0 |
Ethanol/metabolism | 7 | 31.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 4 | 12.0 |
Hepatitis C/complications | 2 | 9.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Isoenzymes/genetics/*metabolism | 8 | 8.0 |
Oxidative Stress/*physiology | 2 | 2.0 |
Cell Division | 3 | 0.0 |
*Alleles | 6 | 0.0 |
Mixed Function Oxygenases/genetics | 3 | 7.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
African Continental Ancestry Group | 2 | 0.0 |
European Continental Ancestry Group | 5 | 0.0 |
Biological Markers/*analysis | 2 | 1.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors/immunology/*metabolism | 2 | 100.0 |
Nitroso Compounds/metabolism | 2 | 40.0 |
Sulfones/pharmacology | 2 | 13.0 |
Coumarins/metabolism | 4 | 16.0 |
Methoxsalen/pharmacology | 2 | 25.0 |
Molecular Structure | 6 | 0.0 |
*Monoterpenes | 3 | 30.0 |
Spectrophotometry | 4 | 2.0 |
Genes, Reporter | 4 | 0.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Glucuronosyltransferase/*metabolism | 2 | 3.0 |
Hepatocytes/*drug effects/*enzymology | 3 | 42.0 |
Algorithms | 4 | 1.0 |
Antifungal Agents/pharmacology | 3 | 7.0 |
Ditiocarb/*pharmacology | 2 | 25.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/metabolism | 2 | 18.0 |
Spodoptera | 2 | 0.0 |
Aldehydes/*metabolism | 2 | 14.0 |
Lipid Peroxides/metabolism | 3 | 16.0 |
Liver/*metabolism/pathology | 2 | 6.0 |
Liver Cirrhosis, Alcoholic/metabolism | 2 | 28.0 |
Liver Diseases, Alcoholic/*metabolism/pathology | 2 | 66.0 |
Malondialdehyde/metabolism | 2 | 7.0 |
Proteins/metabolism | 3 | 0.0 |
Stereoisomerism | 8 | 2.0 |
Cytochrome P-450 CYP2E1/*physiology | 6 | 85.0 |
*Mice, Knockout | 2 | 15.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 15 | 12.0 |
Mutagens/*toxicity | 6 | 5.0 |
Plasmids | 5 | 0.0 |
Salmonella typhimurium/*genetics | 2 | 28.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Protein Biosynthesis | 4 | 0.0 |
DNA, Complementary/biosynthesis | 5 | 8.0 |
Methylation | 8 | 1.0 |
Acetaminophen/*pharmacokinetics | 3 | 75.0 |
Analgesics, Non-Narcotic/*pharmacokinetics | 2 | 66.0 |
Dealkylation | 10 | 17.0 |
Dextromethorphan/metabolism | 2 | 18.0 |
Benzene/*pharmacokinetics | 3 | 100.0 |
Lung/*enzymology | 10 | 15.0 |
United States | 5 | 0.0 |
Cytochrome P-450 Enzyme System/classification/*genetics/metabolism | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Allyl Compounds/*metabolism | 2 | 100.0 |
Epoxy Compounds/*metabolism | 6 | 42.0 |
Lung/*metabolism | 2 | 2.0 |
Clinical Trials | 3 | 0.0 |
Acetaldehyde/*metabolism | 2 | 40.0 |
Alcohol Dehydrogenase/metabolism | 4 | 66.0 |
Brain/embryology/*enzymology | 3 | 37.0 |
Cytochrome P-450 CYP2E1/genetics/*physiology | 3 | 100.0 |
*Gene Expression Regulation, Enzymologic | 10 | 2.0 |
Neoplasms/etiology | 2 | 5.0 |
Blood Glucose/analysis | 2 | 0.0 |
Lipids/blood | 2 | 0.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 3 | 10.0 |
Fetus | 4 | 0.0 |
Gestational Age | 4 | 0.0 |
Troleandomycin/pharmacology | 3 | 5.0 |
Carbon Radioisotopes/diagnostic use | 2 | 3.0 |
Spectrum Analysis, Mass | 5 | 0.0 |
Crystallization | 2 | 0.0 |
Hydrophobicity | 2 | 2.0 |
DNA/metabolism | 2 | 0.0 |
Cytochrome P-450 CYP2E1/antagonists & inhibitors | 3 | 75.0 |
*Diet | 6 | 2.0 |
Mixed Function Oxygenases/biosynthesis | 3 | 21.0 |
Alcohol Drinking/*adverse effects | 5 | 13.0 |
Cocarcinogenesis | 3 | 11.0 |
Brazil/epidemiology | 3 | 3.0 |
Japan/ethnology | 2 | 2.0 |
Isoenzymes/*genetics | 9 | 2.0 |
Human Growth Hormone/*pharmacology | 2 | 5.0 |
Gene Library | 3 | 0.0 |
Anti-Arrhythmia Agents/metabolism | 2 | 100.0 |
Statistics | 3 | 0.0 |
Liver/enzymology/*metabolism | 2 | 5.0 |
Prospective Studies | 6 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Sequence Analysis, DNA | 8 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Cysteine Proteinase Inhibitors/pharmacology | 3 | 1.0 |
Protective Agents/*pharmacology | 4 | 50.0 |
Butadienes/*metabolism | 2 | 66.0 |
Cytochrome P-450 CYP1A1/*antagonists & inhibitors/genetics | 2 | 100.0 |
Down-Regulation | 3 | 0.0 |
Methylcholanthrene/pharmacology | 2 | 5.0 |
Mixed Function Oxygenases/biosynthesis/metabolism | 3 | 100.0 |
Phenobarbital/pharmacology | 5 | 8.0 |
Rifampin/pharmacology | 3 | 4.0 |
beta-Naphthoflavone/pharmacology | 2 | 6.0 |
Infusions, Intravenous | 3 | 0.0 |
Isoenzymes/*antagonists & inhibitors | 6 | 18.0 |
Citrus/*metabolism | 2 | 40.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 5 | 17.0 |
Liver/drug effects/enzymology | 9 | 13.0 |
Metabolic Clearance Rate | 8 | 2.0 |
Microsomes/*enzymology | 9 | 20.0 |
Structure-Activity Relationship | 7 | 0.0 |
Risk | 6 | 0.0 |
*Anesthesia, Inhalation | 2 | 40.0 |
Fluorides/*blood | 2 | 100.0 |
NADPH-Ferrihemoprotein Reductase | 3 | 23.0 |
Alcoholism/*enzymology | 3 | 21.0 |
Epoxide Hydrolases/*genetics/metabolism | 2 | 28.0 |
*Gene Expression | 5 | 0.0 |
Smoking/urine | 2 | 40.0 |
Dextromethorphan/*metabolism | 2 | 50.0 |
Swine | 7 | 0.0 |
Carcinogenicity Tests | 3 | 3.0 |
*Chromosome Aberrations | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Lymphocytes/drug effects | 2 | 2.0 |
Pharmacogenetics/*methods | 2 | 11.0 |
*Phenotype | 3 | 1.0 |
DNA Damage/*drug effects | 2 | 4.0 |
Islets of Langerhans/*drug effects/metabolism | 2 | 33.0 |
Carcinoma, Hepatocellular/*enzymology/*pathology | 2 | 66.0 |
Cell Differentiation | 4 | 0.0 |
Cytochrome P-450 CYP2E1/*biosynthesis/*pharmacology | 2 | 100.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Liver Neoplasms/*enzymology/*pathology | 2 | 66.0 |
Phenobarbital/adverse effects | 2 | 22.0 |
Phenytoin/adverse effects | 2 | 12.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis/genetics/metabolism | 2 | 100.0 |
Brain/drug effects/*enzymology | 2 | 18.0 |
Cytochrome P-450 CYP2D6/biosynthesis/genetics/metabolism | 2 | 100.0 |
Cytochrome P-450 CYP2E1/biosynthesis/genetics/metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics/*metabolism | 3 | 37.0 |
Oxidoreductases, N-Demethylating/biosynthesis/genetics/metabolism | 2 | 100.0 |
Biotransformation/*genetics | 2 | 33.0 |
Acetylcysteine/analogs & derivatives/urine | 2 | 100.0 |
Sorbic Acid/analogs & derivatives/metabolism | 2 | 100.0 |
*Variation (Genetics) | 3 | 0.0 |
Microsomes/drug effects/enzymology | 3 | 15.0 |
Immunization | 2 | 0.0 |
Vaccinia virus/genetics | 3 | 4.0 |
Alcoholism/complications | 4 | 19.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Cytochrome P-450 CYP2E1/*analysis | 2 | 100.0 |
*Risk Assessment | 2 | 11.0 |
DNA/biosynthesis | 2 | 0.0 |
Aging/metabolism | 2 | 1.0 |
Microsomes, Liver/enzymology/*metabolism | 7 | 9.0 |
Cytochrome P-450 Enzyme System/biosynthesis/metabolism | 2 | 25.0 |
Liver Function Tests | 8 | 4.0 |
Biological Markers/blood | 2 | 0.0 |
Cytochromes b5/metabolism | 3 | 37.0 |
NADP/pharmacology | 6 | 27.0 |
Tretinoin/*metabolism | 2 | 4.0 |
Steroid Hydroxylases/*genetics | 2 | 2.0 |
*Transcription, Genetic | 4 | 0.0 |
Fetus/*metabolism | 3 | 3.0 |
Liver Circulation | 2 | 11.0 |
Perfusion | 2 | 0.0 |
Arachidonic Acid/metabolism | 3 | 3.0 |
Hydroxyeicosatetraenoic Acids/*biosynthesis | 2 | 66.0 |
Kidney Tubules/metabolism | 2 | 6.0 |
Microsomes/enzymology/metabolism | 4 | 23.0 |
Templates, Genetic | 3 | 1.0 |
Breath Tests | 3 | 4.0 |
Chlorzoxazone/pharmacokinetics | 3 | 100.0 |
Animals, Genetically Modified | 2 | 0.0 |
Sex Factors | 13 | 0.0 |
Hospital Costs/statistics & numerical data | 2 | 8.0 |
Socioeconomic Factors | 2 | 1.0 |
Estradiol/*metabolism | 2 | 3.0 |
Estrone/*metabolism | 2 | 33.0 |
Indians, North American/genetics | 2 | 5.0 |
Lymphocytes/*enzymology | 3 | 4.0 |
Food Contamination | 3 | 10.0 |
Serum Albumin/metabolism | 2 | 1.0 |
DNA Fragmentation | 2 | 0.0 |
Microsomes, Liver/*drug effects/*enzymology | 2 | 40.0 |
Erythromycin/*pharmacology | 2 | 9.0 |
Fatty Acids/*metabolism | 2 | 2.0 |
Haplorhini | 4 | 1.0 |
Immunoblotting | 9 | 0.0 |
Pharmacokinetics | 6 | 16.0 |
Isoenzymes/genetics/metabolism | 9 | 6.0 |
DNA Primers/genetics | 5 | 0.0 |
Biliary Tract/*enzymology | 2 | 100.0 |
Epoxide Hydrolases/genetics/metabolism | 4 | 66.0 |
Gallbladder/cytology/*enzymology | 2 | 100.0 |
Liver/cytology/enzymology | 2 | 25.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 6 | 33.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Acetaldehyde/*pharmacology | 3 | 60.0 |
Cyanamide/pharmacology | 2 | 66.0 |
DNA/genetics/metabolism | 5 | 1.0 |
Liver/cytology/drug effects/enzymology/*metabolism | 2 | 100.0 |
Transcription Factor AP-1/*metabolism | 2 | 1.0 |
Liver/cytology/*drug effects/enzymology | 3 | 25.0 |
*Embryonic and Fetal Development | 3 | 2.0 |
Cross Reactions | 6 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*immunology | 2 | 66.0 |
Spodoptera/virology | 2 | 25.0 |
Testosterone/metabolism | 7 | 5.0 |
Alcohol Drinking/metabolism | 3 | 37.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Plants, Toxic | 3 | 7.0 |
Smoking/*adverse effects | 7 | 3.0 |
Enzyme Stability | 2 | 1.0 |
NADP/*metabolism | 3 | 10.0 |
Liver/*drug effects/metabolism | 2 | 4.0 |
Ursodeoxycholic Acid/*pharmacology | 2 | 66.0 |
Hepatocytes/enzymology | 3 | 20.0 |
Nitrophenols/*metabolism | 2 | 66.0 |
Oxidoreductases, N-Demethylating/biosynthesis/metabolism | 2 | 66.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 3 | 6.0 |
Carcinoma, Hepatocellular/enzymology | 2 | 11.0 |
Indoles/metabolism/pharmacology | 2 | 33.0 |
Liver Neoplasms/enzymology | 2 | 14.0 |
Oxazines/metabolism | 4 | 18.0 |
Umbelliferones/metabolism | 2 | 33.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
Liver/cytology/*enzymology/metabolism | 2 | 100.0 |
Oxidoreductases/metabolism | 4 | 5.0 |
Superoxides/metabolism | 2 | 0.0 |
Cloning, Molecular | 11 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Chlorzoxazone/analogs & derivatives/metabolism | 2 | 100.0 |
Half-Life | 8 | 1.0 |
Biotransformation/drug effects | 3 | 10.0 |
Food-Drug Interactions | 2 | 6.0 |
Isoenzymes/biosynthesis/*genetics | 2 | 11.0 |
Cytochrome P-450 CYP2E1/*analysis/genetics | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*analysis/genetics | 2 | 25.0 |
Chlormethiazole/*pharmacology | 2 | 100.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Hypnotics and Sedatives/*metabolism | 2 | 28.0 |
Indicators and Reagents | 2 | 0.0 |
Biological Availability | 5 | 1.0 |
Cytochrome P-450 Enzyme System/drug effects/metabolism | 3 | 42.0 |
Feces/chemistry | 3 | 6.0 |
Chromatography, High Pressure Liquid/methods | 4 | 2.0 |
Acetylation | 6 | 1.0 |
Arylamine N-Acetyltransferase/*genetics | 7 | 3.0 |
Carcinogens/metabolism | 2 | 6.0 |
*Meat | 2 | 4.0 |
*Drug Interactions | 4 | 17.0 |
Benzene/*metabolism | 2 | 66.0 |
Carcinogens/*metabolism | 6 | 7.0 |
*Models, Biological | 2 | 1.0 |
Antibodies, Blocking/pharmacology | 3 | 3.0 |
Aniline Compounds/pharmacology | 2 | 18.0 |
Baculoviridae/genetics | 3 | 1.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/*metabolism | 3 | 23.0 |
Fluvoxamine/pharmacology | 2 | 14.0 |
Cell Survival/drug effects/physiology | 3 | 3.0 |
Nifedipine/metabolism | 2 | 11.0 |
Exons/genetics | 4 | 0.0 |
Introns/genetics | 5 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Cytochrome P-450 CYP2E1/*analysis/metabolism | 2 | 100.0 |
History, 20th Century | 2 | 1.0 |
DNA Probes | 2 | 0.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 4 | 11.0 |
Oxygenases/*metabolism | 2 | 8.0 |
Anisoles/*metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 5 | 33.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 7 | 15.0 |
Isoenzymes/biosynthesis/genetics | 3 | 6.0 |
DNA | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Mixed Function Oxygenases/*physiology | 4 | 12.0 |
Oxidoreductases, N-Demethylating/*physiology | 2 | 20.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
*Gene Expression Regulation, Developmental | 4 | 0.0 |
*Genotype | 12 | 5.0 |
Mutation, Missense | 2 | 0.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Uric Acid/analogs & derivatives/metabolism | 3 | 75.0 |
Xanthines/metabolism | 2 | 40.0 |
Anticonvulsants/*pharmacology | 2 | 10.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Hydrolysis | 2 | 0.0 |
Solubility | 3 | 0.0 |
Water | 2 | 3.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
Theophylline/analogs & derivatives/pharmacology | 5 | 22.0 |
Trifluoroacetic Acid/blood/urine | 2 | 100.0 |
Cytosol/metabolism | 4 | 0.0 |
Fetus/metabolism | 2 | 1.0 |
*Lipid Peroxidation | 3 | 6.0 |
Mucous Membrane/enzymology | 2 | 18.0 |
Head and Neck Neoplasms/enzymology/*genetics | 2 | 33.0 |
Pharyngeal Neoplasms/genetics | 2 | 28.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 3 | 18.0 |
Signal Transduction | 2 | 0.0 |
Genetic Heterogeneity | 2 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Antidotes/pharmacology | 2 | 66.0 |
Cell Line/drug effects | 2 | 4.0 |
Laryngeal Neoplasms/*genetics | 2 | 11.0 |
Lung Neoplasms/etiology | 3 | 27.0 |
Cytochrome P-450 CYP1A1/*genetics/metabolism | 2 | 9.0 |
Antibody Specificity | 6 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
Autoradiography | 2 | 0.0 |
Midazolam/pharmacokinetics | 3 | 25.0 |
Carcinogens/*pharmacokinetics | 2 | 8.0 |
Reactive Oxygen Species | 4 | 3.0 |
Xenobiotics/*pharmacokinetics | 4 | 25.0 |
Lethal Dose 50 | 2 | 3.0 |
Liver/metabolism/pathology | 3 | 6.0 |
*Genes, p53 | 2 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 3 | 2.0 |
Ethanol/*pharmacokinetics | 6 | 40.0 |
Liver Diseases, Alcoholic/enzymology | 2 | 66.0 |
Trimethadione/*metabolism | 2 | 50.0 |
Aging/*metabolism | 4 | 1.0 |
Isomerism | 4 | 1.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/pharmacology | 2 | 28.0 |
Clofibrate/pharmacology | 2 | 9.0 |
Aldehyde Dehydrogenase/*genetics/metabolism | 2 | 15.0 |
Least-Squares Analysis | 2 | 5.0 |
*Sister Chromatid Exchange | 2 | 6.0 |
Blotting, Southern | 6 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
*Point Mutation | 2 | 0.0 |
Alcoholism/*enzymology/*genetics | 3 | 75.0 |
Carcinogens/*metabolism/toxicity | 3 | 18.0 |
Organ Culture Techniques | 2 | 0.0 |
Chlorzoxazone/*metabolism | 9 | 100.0 |
Arachidonic Acid/antagonists & inhibitors/pharmacology | 2 | 100.0 |
Calcium/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Ethanol | 2 | 9.0 |
Obesity/*metabolism | 2 | 2.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Restriction Mapping | 5 | 0.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Antineoplastic Agents/*pharmacokinetics | 2 | 15.0 |
Disulfiram/*pharmacokinetics | 2 | 100.0 |
Asian Continental Ancestry Group | 5 | 1.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Isoenzymes/physiology | 2 | 4.0 |
Indians, South American/*genetics | 2 | 3.0 |
Deoxyribonucleases, Type II Site-Specific | 6 | 2.0 |
Biopsy | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
Benzoflavones/pharmacology | 4 | 8.0 |
Muscle Relaxants, Central/*metabolism | 3 | 100.0 |
Immunochemistry | 2 | 0.0 |
Liver/cytology/*metabolism | 3 | 4.0 |
Solvents/*metabolism | 2 | 100.0 |
Toluene/*metabolism | 4 | 50.0 |
Analgesics, Opioid/*metabolism | 2 | 40.0 |
Alcoholism/*metabolism | 2 | 25.0 |
Antimutagenic Agents/*pharmacology | 2 | 13.0 |
*DNA Damage | 8 | 1.0 |
Dimethylnitrosamine/*toxicity | 2 | 100.0 |
Chromans/*pharmacology | 2 | 7.0 |
Monoamine Oxidase Inhibitors/*pharmacology | 2 | 22.0 |
Terpenes/*pharmacology | 2 | 10.0 |
HIV Protease Inhibitors/*pharmacology | 2 | 7.0 |
Gene Expression Regulation, Enzymologic/drug effects | 4 | 2.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*metabolism | 5 | 20.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Cytochrome P-450 Enzyme System/analysis/*metabolism | 2 | 28.0 |
Free Radicals | 5 | 3.0 |
beta-Naphthoflavone | 2 | 11.0 |
Ethanol/metabolism/*pharmacology | 3 | 100.0 |
DNA Repair | 3 | 0.0 |
United States/epidemiology | 3 | 0.0 |
Diabetes Mellitus, Type 1/*metabolism | 2 | 3.0 |
Placenta/*enzymology | 5 | 6.0 |
Kidney/*enzymology | 4 | 5.0 |
Antidepressive Agents/*pharmacology | 2 | 7.0 |
Adenosine Triphosphate/metabolism | 3 | 0.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Cell Division/drug effects | 7 | 0.0 |
Polymorphism, Genetic/genetics | 8 | 1.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
Environmental Pollutants/*pharmacokinetics | 3 | 100.0 |
Mixed Function Oxygenases/antagonists & inhibitors/immunology/*metabolism | 2 | 40.0 |
Mutagenicity Tests/methods | 2 | 16.0 |
Oxidoreductases, N-Demethylating/genetics | 5 | 45.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Liver/embryology/*enzymology | 2 | 18.0 |
Xenobiotics/adverse effects/*metabolism | 2 | 100.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Random Allocation | 2 | 0.0 |
Microsomes, Liver/drug effects/*enzymology/metabolism | 2 | 22.0 |
Electrophoresis | 2 | 0.0 |
Biotransformation/genetics | 2 | 22.0 |
Cytochrome P-450 CYP2E1/*genetics/physiology | 2 | 100.0 |
Smoking/adverse effects/metabolism | 2 | 40.0 |
Fatty Liver/*enzymology/pathology | 2 | 100.0 |
Mutagens/*metabolism | 3 | 8.0 |
Neoplasms/*etiology | 3 | 11.0 |
Drug Evaluation, Preclinical/methods | 2 | 6.0 |
Isoenzymes/*biosynthesis/genetics | 2 | 8.0 |
Stomach Neoplasms/epidemiology/*genetics | 2 | 16.0 |
Environmental Exposure | 3 | 2.0 |
Lung/enzymology | 2 | 3.0 |
Macrophages, Alveolar/*enzymology | 2 | 22.0 |
*Alcoholic Beverages | 2 | 40.0 |
Rats, Inbred Strains | 3 | 0.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 2 | 3.0 |
Anesthetics, Inhalation/*metabolism | 2 | 100.0 |
Escherichia coli/genetics | 2 | 0.0 |
Recombinant Proteins/*biosynthesis | 2 | 5.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Cadaver | 2 | 0.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Styrene | 3 | 42.0 |
Styrenes/*metabolism | 2 | 100.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 2 | 13.0 |
Ethanolamines/metabolism | 2 | 11.0 |
Ascorbic Acid/pharmacology | 2 | 3.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 2 | 13.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Cytochromes/metabolism | 2 | 33.0 |
Enzyme Induction/*drug effects | 3 | 17.0 |
Disease Susceptibility/enzymology | 2 | 40.0 |
RNA/analysis | 2 | 0.0 |
Alcohol Drinking/genetics | 3 | 30.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Epoxy Compounds/toxicity | 2 | 66.0 |
Methionine/metabolism | 2 | 1.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Age of Onset | 3 | 0.0 |
Chlorzoxazone/*metabolism/pharmacokinetics | 2 | 100.0 |
Spectrometry, Fluorescence | 4 | 0.0 |
Lauric Acids/metabolism | 2 | 22.0 |
Lymphocytes/enzymology | 4 | 4.0 |
*Vegetables | 2 | 15.0 |
Metabolic Detoxication, Drug/genetics | 2 | 10.0 |
Isoenzymes/*antagonists & inhibitors/metabolism | 2 | 20.0 |
Placenta/enzymology | 2 | 2.0 |
Dimethyl Sulfoxide/*pharmacology | 2 | 8.0 |
Oxidoreductases, N-Demethylating/genetics/*metabolism | 4 | 40.0 |
Cytochrome P-450 CYP2E1/immunology/metabolism | 2 | 100.0 |
Liver/drug effects | 3 | 8.0 |
Muscle Relaxants, Central/*pharmacology | 2 | 66.0 |
Isoenzymes/immunology/*metabolism | 2 | 33.0 |
Sex Characteristics | 4 | 0.0 |
Carcinogens/*toxicity | 3 | 2.0 |
Vinyl Chloride/*toxicity | 3 | 75.0 |
*Helicobacter pylori | 2 | 1.0 |
Pepsinogens/blood | 2 | 28.0 |
Lung Neoplasms/*enzymology/*genetics | 3 | 25.0 |
Liver Diseases, Alcoholic/enzymology/genetics | 2 | 100.0 |
Enzyme Inhibitors/*metabolism | 2 | 2.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/*metabolism | 2 | 22.0 |
*Allyl Compounds | 2 | 100.0 |
Otorhinolaryngologic Neoplasms/*genetics | 2 | 66.0 |
Quinolines/*metabolism | 2 | 11.0 |
Culture Media | 3 | 0.0 |
Mutagens/toxicity | 3 | 8.0 |
Alcoholism/*complications | 2 | 10.0 |
Microsomes, Liver/*drug effects/*metabolism | 2 | 40.0 |
Family Health | 2 | 0.0 |
Japan/epidemiology | 3 | 0.0 |
Syndrome | 2 | 0.0 |
Antipsychotic Agents/chemistry/*metabolism | 2 | 100.0 |
Phenothiazines/chemistry/*metabolism | 2 | 100.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/*genetics | 2 | 18.0 |
Fetus/enzymology | 2 | 7.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*immunology | 2 | 28.0 |
Xenobiotics/*toxicity | 2 | 20.0 |
Microsomes, Liver/*enzymology/metabolism | 2 | 6.0 |
Body Weight | 2 | 0.0 |
Saliva/metabolism | 2 | 6.0 |
Nitrosamines/metabolism | 3 | 50.0 |
Microsomes/*metabolism | 3 | 7.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/metabolism | 4 | 30.0 |
Arachidonic Acid/antagonists & inhibitors/toxicity | 2 | 100.0 |
Cell Line, Tumor | 4 | 0.0 |
Mitochondria/drug effects/physiology | 3 | 11.0 |
Smoking/*genetics | 2 | 4.0 |
Metabolic Clearance Rate/genetics | 2 | 22.0 |
Oxidoreductases, N-Demethylating/*genetics | 19 | 44.0 |
Alcoholism/ethnology/*genetics | 2 | 22.0 |
Oxidoreductases, N-Demethylating/*biosynthesis/metabolism | 3 | 50.0 |
Neoplasms/*chemically induced/genetics | 2 | 66.0 |
Caffeine/*pharmacokinetics | 3 | 17.0 |
Central Nervous System Stimulants/*pharmacokinetics | 2 | 22.0 |
Pyrazoles/metabolism | 2 | 40.0 |
Bilirubin/blood | 2 | 2.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Oxidoreductases/*genetics/metabolism | 3 | 15.0 |
Oxidoreductases, N-Demethylating/*genetics/*metabolism | 3 | 50.0 |
Oxidoreductases, N-Demethylating/*biosynthesis | 2 | 11.0 |
Oxidoreductases, N-Demethylating/*genetics/metabolism | 2 | 28.0 |
Arachidonic Acid/*metabolism | 2 | 5.0 |
Cytochrome P-450 CYP1A2 | 6 | 6.0 |
Oxidoreductases/*metabolism | 2 | 4.0 |
Cytochrome P-450 CYP2D6 | 6 | 8.0 |
Enzymes/*genetics | 2 | 4.0 |
Microsomes/drug effects/metabolism | 2 | 10.0 |
Epoxide Hydrolases/genetics/*metabolism | 3 | 60.0 |
Flushing/genetics | 4 | 57.0 |
Mitochondria, Liver/enzymology | 2 | 8.0 |
Lung/metabolism | 3 | 1.0 |
Deoxyribonuclease I | 2 | 1.0 |
*Nuclear Proteins | 2 | 0.0 |
Chlorzoxazone/analogs & derivatives/*pharmacokinetics | 2 | 100.0 |
Enzyme Induction/physiology | 2 | 15.0 |
Oxidoreductases/genetics/metabolism | 3 | 25.0 |
Theophylline/*metabolism | 2 | 40.0 |
Leucyl Aminopeptidase/*blood | 2 | 40.0 |
Molecular Probes | 2 | 3.0 |
Brazil | 3 | 1.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Carcinoma, Hepatocellular/enzymology/*genetics | 2 | 20.0 |
Liver Neoplasms/enzymology/*genetics | 2 | 18.0 |
*Disease Models, Animal | 2 | 0.0 |
Insulin/blood | 2 | 0.0 |
Insulin Resistance | 2 | 1.0 |
Ethylene Glycols/metabolism | 2 | 40.0 |
Aldehyde Oxidoreductases/*genetics | 2 | 11.0 |
Safety | 2 | 1.0 |
Haplotypes | 2 | 0.0 |
Cytochrome P-450 Enzyme System/classification/*genetics | 2 | 40.0 |
Esterases/*genetics | 2 | 2.0 |
Xenobiotics/pharmacology | 2 | 8.0 |
Micronuclei, Chromosome-Defective/drug effects | 2 | 33.0 |
Continental Population Groups/genetics | 5 | 5.0 |
Predictive Value of Tests | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/*drug effects/physiology | 2 | 33.0 |
Antioxidants/*therapeutic use | 2 | 6.0 |
Severity of Illness Index | 2 | 0.0 |
Caffeine/metabolism/*pharmacokinetics | 2 | 100.0 |
Fluorometry | 3 | 4.0 |
Mice, Inbred DBA | 2 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Cytochrome P-450 CYP2E1/*pharmacology | 2 | 100.0 |
Papillomavirus, Human | 2 | 5.0 |
Korea/epidemiology | 2 | 3.0 |
Caco-2 Cells | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Oligonucleotide Probes | 3 | 0.0 |
Reactive Oxygen Species/antagonists & inhibitors | 2 | 66.0 |
Promoter Regions (Genetics)/*drug effects | 2 | 4.0 |
Fatty Liver/*metabolism/pathology | 2 | 100.0 |
Cytochrome P-450 CYP2E1/analysis/*genetics | 2 | 100.0 |
Genetic Predisposition to Disease/epidemiology/*genetics | 2 | 11.0 |
*Contrast Media | 2 | 7.0 |
ATP-Binding Cassette Transporters/*metabolism | 2 | 2.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Dietary Supplements | 2 | 2.0 |
Hepatitis C/*complications | 2 | 11.0 |
Liver Neoplasms/*etiology | 2 | 16.0 |
Mutation/genetics | 2 | 0.0 |
Infant, Premature/*metabolism | 2 | 10.0 |
Carotenoids/*pharmacology | 2 | 33.0 |
Transduction, Genetic | 2 | 0.0 |
Styrene/*toxicity | 2 | 28.0 |
Chlorzoxazone/diagnostic use/pharmacokinetics | 2 | 100.0 |
Oxidative Stress/physiology | 2 | 2.0 |
DNA, Complementary/biosynthesis/genetics | 3 | 6.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Alcoholism/enzymology/*genetics | 2 | 20.0 |
Cytochrome P-450 CYP2E1/biosynthesis | 2 | 66.0 |
Liver Transplantation/*physiology | 2 | 10.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 2 | 11.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 2 | 13.0 |
Cytochrome P-450 CYP2E1/*genetics/pharmacology | 2 | 100.0 |
Glutathione Transferase/*genetics/pharmacology | 2 | 18.0 |
Occupational Exposure/adverse effects/*analysis | 2 | 40.0 |
Isoniazid/pharmacology | 2 | 22.0 |
Herb-Drug Interactions | 2 | 25.0 |
5' Flanking Region/genetics | 2 | 2.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Aflatoxin B1/toxicity | 2 | 22.0 |
Analgesics, Non-Narcotic/*poisoning | 2 | 66.0 |
